Figure 3.
Comparable expansion of tumor-specific effectors from blood and marrow T cells. Blood or marrow T cells were cultured with unpulsed or tumor cell-loaded DCs for 12–16 days. After expansion, the presence of tumor-reactive T cells was quantified with an ELISPOT assay by using autologous tumor (CD138+) or nontumor (CD138-ve) bone marrow cells as APCs, as described (7).